A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury

Am J Pathol. 2004 Feb;164(2):521-32. doi: 10.1016/s0002-9440(10)63142-2.

Abstract

Cytochrome P450 (CYP)-dependent arachidonic acid (AA) metabolites are involved in the regulation of renal vascular tone and salt excretion. The epoxygenation product 11,12-epoxyeicosatrienoic acid (EET) is anti-inflammatory and inhibits nuclear factor-kappa B activation. We tested the hypothesis that the peroxisome proliferator-activated receptor-alpha-activator fenofibrate (Feno) induces CYP isoforms, AA hydroxylation, and epoxygenation activity, and protects against inflammatory organ damage. Double-transgenic rats (dTGRs) overexpressing human renin and angiotensinogen genes were treated with Feno. Feno normalized blood pressure, albuminuria, reduced nuclear factor-kappa B activity, and renal leukocyte infiltration. Renal epoxygenase activity was lower in dTGRs compared to nontransgenic rats. Feno strongly induced renal CYP2C23 protein and AA-epoxygenase activity under pathological and nonpathological conditions. In both cases, CYP2C23 was the major isoform responsible for 11,12-EET formation. Moreover, we describe a novel CYP2C23-dependent pathway leading to hydroxy-EETs (HEETs), which may serve as endogenous peroxisome proliferator-activated receptor-alpha activators. The capacity to produce HEETs via CYP2C23-dependent epoxygenation of 20-HETE and CYP4A-dependent hydroxylation of EETs was reduced in dTGR kidneys and induced by Feno. These results demonstrate that Feno protects against angiotensin II-induced renal damage and acts as inducer of CYP2C23-mediated epoxygenase activities. We propose that CYP-dependent EET/HEET production may serve as an anti-inflammatory control mechanism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives*
  • 8,11,14-Eicosatrienoic Acid / metabolism
  • Angiotensin II / pharmacology
  • Angiotensinogen / genetics
  • Animals
  • Animals, Genetically Modified
  • Arachidonic Acid / metabolism*
  • Blotting, Western
  • Chromatography, Liquid
  • Cytochrome P-450 CYP2J2
  • Cytochrome P-450 Enzyme System / drug effects*
  • Cytochrome P-450 Enzyme System / metabolism*
  • Fenofibrate / pharmacology
  • Humans
  • Hypertension / drug therapy
  • Hypertension / etiology
  • Hypolipidemic Agents / pharmacology
  • Immunohistochemistry
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney Diseases / complications
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / pathology
  • Mass Spectrometry
  • NF-kappa B / drug effects
  • Polymerase Chain Reaction
  • Rats
  • Receptors, Cytoplasmic and Nuclear / drug effects*
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Renin / genetics
  • Transcription Factors / drug effects*
  • Transcription Factors / metabolism
  • Vasoconstrictor Agents / pharmacology

Substances

  • Cyp2c23 protein, rat
  • Hypolipidemic Agents
  • NF-kappa B
  • Receptors, Cytoplasmic and Nuclear
  • Transcription Factors
  • Vasoconstrictor Agents
  • Angiotensinogen
  • Angiotensin II
  • Arachidonic Acid
  • 11,12-epoxy-5,8,14-eicosatrienoic acid
  • Cytochrome P-450 Enzyme System
  • Cytochrome P-450 CYP2J2
  • Renin
  • 8,11,14-Eicosatrienoic Acid
  • Fenofibrate